BIOSYENT INC (RX.CA) Stock Fundamental Analysis
Canada - TSX Venture Exchange - TSX-V:RX - CA0906901081 - Common Stock
12.84 CAD
-0.01 (-0.08%)
RX gets a fundamental rating of 8 out of 10. The analysis compared the fundamentals against 33 industry peers in the Pharmaceuticals industry. Both the health and profitability get an excellent rating, making RX a very profitable company, without any liquidiy or solvency issues. RX is growing strongly while it is still valued neutral. This is a good combination! These ratings would make RX suitable for growth and quality investing!
1. Profitability
1.1 Basic Checks
- RX had positive earnings in the past year.
- In the past year RX had a positive cash flow from operations.
- Each year in the past 5 years RX has been profitable.
- In the past 5 years RX always reported a positive cash flow from operatings.
1.2 Ratios
- With an excellent Return On Assets value of 18.07%, RX belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
- RX has a better Return On Equity (21.64%) than 93.94% of its industry peers.
- The Return On Invested Capital of RX (20.81%) is better than 96.97% of its industry peers.
- RX had an Average Return On Invested Capital over the past 3 years of 16.58%. This is significantly above the industry average of 8.78%.
- The 3 year average ROIC (16.58%) for RX is below the current ROIC(20.81%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.07% | ||
| ROE | 21.64% | ||
| ROIC | 20.81% |
ROA(3y)15.54%
ROA(5y)14.96%
ROE(3y)18.57%
ROE(5y)17.96%
ROIC(3y)16.58%
ROIC(5y)16.4%
1.3 Margins
- The Profit Margin of RX (20.47%) is better than 87.88% of its industry peers.
- RX's Profit Margin has been stable in the last couple of years.
- With an excellent Operating Margin value of 26.75%, RX belongs to the best of the industry, outperforming 90.91% of the companies in the same industry.
- RX's Operating Margin has declined in the last couple of years.
- RX has a better Gross Margin (77.46%) than 96.97% of its industry peers.
- RX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 26.75% | ||
| PM (TTM) | 20.47% | ||
| GM | 77.46% |
OM growth 3Y-3.53%
OM growth 5Y-2.73%
PM growth 3Y-1.85%
PM growth 5Y0.35%
GM growth 3Y0.17%
GM growth 5Y0.46%
2. Health
2.1 Basic Checks
- RX has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
- RX has less shares outstanding than it did 1 year ago.
- RX has less shares outstanding than it did 5 years ago.
- Compared to 1 year ago, RX has an improved debt to assets ratio.
2.2 Solvency
- An Altman-Z score of 14.57 indicates that RX is not in any danger for bankruptcy at the moment.
- RX's Altman-Z score of 14.57 is amongst the best of the industry. RX outperforms 100.00% of its industry peers.
- The Debt to FCF ratio of RX is 0.11, which is an excellent value as it means it would take RX, only 0.11 years of fcf income to pay off all of its debts.
- The Debt to FCF ratio of RX (0.11) is better than 100.00% of its industry peers.
- A Debt/Equity ratio of 0.02 indicates that RX is not too dependend on debt financing.
- RX's Debt to Equity ratio of 0.02 is fine compared to the rest of the industry. RX outperforms 75.76% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.11 | ||
| Altman-Z | 14.57 |
ROIC/WACC2.44
WACC8.51%
2.3 Liquidity
- RX has a Current Ratio of 5.06. This indicates that RX is financially healthy and has no problem in meeting its short term obligations.
- The Current ratio of RX (5.06) is better than 93.94% of its industry peers.
- RX has a Quick Ratio of 4.23. This indicates that RX is financially healthy and has no problem in meeting its short term obligations.
- RX has a better Quick ratio (4.23) than 93.94% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.06 | ||
| Quick Ratio | 4.23 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 24.84% over the past year.
- RX shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 15.02% yearly.
- Looking at the last year, RX shows a very strong growth in Revenue. The Revenue has grown by 22.22%.
- RX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.33% yearly.
EPS 1Y (TTM)24.84%
EPS 3Y8.39%
EPS 5Y15.02%
EPS Q2Q%19.41%
Revenue 1Y (TTM)22.22%
Revenue growth 3Y6.97%
Revenue growth 5Y10.33%
Sales Q2Q%27.9%
3.2 Future
- The Earnings Per Share is expected to grow by 15.80% on average over the next years. This is quite good.
- Based on estimates for the next years, RX will show a quite strong growth in Revenue. The Revenue will grow by 11.07% on average per year.
EPS Next Y20.96%
EPS Next 2Y19.25%
EPS Next 3Y15.8%
EPS Next 5YN/A
Revenue Next Year23.16%
Revenue Next 2Y12.62%
Revenue Next 3Y11.07%
Revenue Next 5YN/A
3.3 Evolution
- The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 20.71, the valuation of RX can be described as rather expensive.
- Based on the Price/Earnings ratio, RX is valued a bit cheaper than 78.79% of the companies in the same industry.
- When comparing the Price/Earnings ratio of RX to the average of the S&P500 Index (27.32), we can say RX is valued slightly cheaper.
- With a Price/Forward Earnings ratio of 14.47, RX is valued correctly.
- 78.79% of the companies in the same industry are more expensive than RX, based on the Price/Forward Earnings ratio.
- RX is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 24.30, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.71 | ||
| Fwd PE | 14.47 |
4.2 Price Multiples
- RX's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. RX is cheaper than 63.64% of the companies in the same industry.
- 69.70% of the companies in the same industry are more expensive than RX, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 18.24 | ||
| EV/EBITDA | 9.51 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- The excellent profitability rating of RX may justify a higher PE ratio.
- RX's earnings are expected to grow with 15.80% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.99
PEG (5Y)1.38
EPS Next 2Y19.25%
EPS Next 3Y15.8%
5. Dividend
5.1 Amount
- With a Yearly Dividend Yield of 1.54%, RX has a reasonable but not impressive dividend return.
- Compared to an average industry Dividend Yield of 0.26, RX pays a better dividend. On top of this RX pays more dividend than 93.94% of the companies listed in the same industry.
- Compared to an average S&P500 Dividend Yield of 1.86, RX has a dividend comparable with the average S&P500 company.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.54% |
5.2 History
- RX has paid a dividend for less than 5 years, so there is no long track record yet.
Dividend Growth(5Y)N/A
Div Incr Years2
Div Non Decr Years2
5.3 Sustainability
- 25.51% of the earnings are spent on dividend by RX. This is a low number and sustainable payout ratio.
DP25.51%
EPS Next 2Y19.25%
EPS Next 3Y15.8%
TSX-V:RX (1/21/2026, 7:00:00 PM)
12.84
-0.01 (-0.08%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-20 2025-11-20
Earnings (Next)03-11 2026-03-11
Inst Owners3.68%
Inst Owner ChangeN/A
Ins Owners17.83%
Ins Owner ChangeN/A
Market Cap147.40M
Revenue(TTM)42.18M
Net Income(TTM)8.63M
Analysts82.86
Price Target13.77 (7.24%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.54% |
Yearly Dividend0.18
Dividend Growth(5Y)N/A
DP25.51%
Div Incr Years2
Div Non Decr Years2
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)3.85%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)4.81%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.71 | ||
| Fwd PE | 14.47 | ||
| P/S | 3.49 | ||
| P/FCF | 18.24 | ||
| P/OCF | 18.11 | ||
| P/B | 3.69 | ||
| P/tB | 4.22 | ||
| EV/EBITDA | 9.51 |
EPS(TTM)0.62
EY4.83%
EPS(NY)0.89
Fwd EY6.91%
FCF(TTM)0.7
FCFY5.48%
OCF(TTM)0.71
OCFY5.52%
SpS3.67
BVpS3.48
TBVpS3.04
PEG (NY)0.99
PEG (5Y)1.38
Graham Number6.96
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.07% | ||
| ROE | 21.64% | ||
| ROCE | 27.74% | ||
| ROIC | 20.81% | ||
| ROICexc | 48.97% | ||
| ROICexgc | 68.62% | ||
| OM | 26.75% | ||
| PM (TTM) | 20.47% | ||
| GM | 77.46% | ||
| FCFM | 19.16% |
ROA(3y)15.54%
ROA(5y)14.96%
ROE(3y)18.57%
ROE(5y)17.96%
ROIC(3y)16.58%
ROIC(5y)16.4%
ROICexc(3y)59.42%
ROICexc(5y)88.26%
ROICexgc(3y)72.91%
ROICexgc(5y)116.75%
ROCE(3y)22.1%
ROCE(5y)21.86%
ROICexgc growth 3Y-33.84%
ROICexgc growth 5Y-15.21%
ROICexc growth 3Y-35.8%
ROICexc growth 5Y-16.72%
OM growth 3Y-3.53%
OM growth 5Y-2.73%
PM growth 3Y-1.85%
PM growth 5Y0.35%
GM growth 3Y0.17%
GM growth 5Y0.46%
F-Score7
Asset Turnover0.88
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.11 | ||
| Debt/EBITDA | 0.06 | ||
| Cap/Depr | 6.81% | ||
| Cap/Sales | 0.14% | ||
| Interest Coverage | 217.41 | ||
| Cash Conversion | 67.01% | ||
| Profit Quality | 93.59% | ||
| Current Ratio | 5.06 | ||
| Quick Ratio | 4.23 | ||
| Altman-Z | 14.57 |
F-Score7
WACC8.51%
ROIC/WACC2.44
Cap/Depr(3y)10.2%
Cap/Depr(5y)10.36%
Cap/Sales(3y)0.16%
Cap/Sales(5y)0.17%
Profit Quality(3y)95.24%
Profit Quality(5y)108.02%
High Growth Momentum
Growth
EPS 1Y (TTM)24.84%
EPS 3Y8.39%
EPS 5Y15.02%
EPS Q2Q%19.41%
EPS Next Y20.96%
EPS Next 2Y19.25%
EPS Next 3Y15.8%
EPS Next 5YN/A
Revenue 1Y (TTM)22.22%
Revenue growth 3Y6.97%
Revenue growth 5Y10.33%
Sales Q2Q%27.9%
Revenue Next Year23.16%
Revenue Next 2Y12.62%
Revenue Next 3Y11.07%
Revenue Next 5YN/A
EBIT growth 1Y37.32%
EBIT growth 3Y3.2%
EBIT growth 5Y7.32%
EBIT Next Year39.54%
EBIT Next 3Y16.91%
EBIT Next 5YN/A
FCF growth 1Y22.97%
FCF growth 3Y23.38%
FCF growth 5Y17.21%
OCF growth 1Y24.46%
OCF growth 3Y22.83%
OCF growth 5Y14.5%
BIOSYENT INC / RX.CA FAQ
What is the fundamental rating for RX stock?
ChartMill assigns a fundamental rating of 8 / 10 to RX.CA.
What is the valuation status for RX stock?
ChartMill assigns a valuation rating of 6 / 10 to BIOSYENT INC (RX.CA). This can be considered as Fairly Valued.
What is the profitability of RX stock?
BIOSYENT INC (RX.CA) has a profitability rating of 9 / 10.
What is the valuation of BIOSYENT INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for BIOSYENT INC (RX.CA) is 20.71 and the Price/Book (PB) ratio is 3.69.
Can you provide the dividend sustainability for RX stock?
The dividend rating of BIOSYENT INC (RX.CA) is 4 / 10 and the dividend payout ratio is 25.51%.